Category Archives: Genetics

Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO Annual … – GlobeNewswire

SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting. Three studies led by Myriad focus on breast cancer risk assessment, and four additional studies will be shared by collaborators that will cover the companys Precise MRD Test, MyChoice CDx HRD Companion Diagnostic Test, and the Myriad Collaborative Research Registry (MCRR). At booth 25014, Myriad will highlight the value of genetic testing and genomic insights in guiding personalized cancer treatment decisions, as well as share information about upcoming product innovations including MRD and liquid biopsy testing.

New Data at ASCO

Oral Presentation: Evaluation of a polygenic risk score as a predictor of early onset triple-negative breast cancer in Black women (Abstract #: 10501) Presenter: Holly J. Pederson, MD, Director, Medical Breast Services, Cleveland Clinic Date: Saturday, June 1, 2024 Time: 3:12 pm CT Description: This study demonstrates that Myriads RiskScore improves upon clinical factors for the prediction of triple-negative breast cancer and early onset (<50 years) triple-negative breast cancer in Black women.

Poster: Comparison of primary versus metastatic tumor tissue sources when designing panels for whole-genome-based tumor-informed ctDNA assays in clear cell renal cell carcinoma (Abstract #3039) Date: Saturday, June 1, 2024 Time: 9:00am 12:00pm CT Description: In a pilot study of patients with oligometastatic renal cell carcinoma, molecular residual disease (MRD) results were largely concordant with mortality status and between monitoring panels composed of thousands of probes identified from either primary or metastatic tumors, suggesting repeat biopsy might not be necessary for long term MRD monitoring.

Poster: Improving a polygenic risk score (PRS) for breast cancer (BC) risk assessment in diverse ancestries(Abstract #: 10533) Date: Monday, June 3, 2024 Time: 1:30 4:30pm CT Description: This study highlights a new 385-SNP PRS component of RiskScore and demonstrates it is well-calibrated, improves upon clinical factors, and outperformed existing PRS in all tested ancestries for the prediction of breast cancer risk.

Poster: Association of polygenic-based breast cancer risk prediction with patient management(Abstract #: 10527) Date: Monday, June 3, 2024 Time: 1:30 4:30pm CT Description: The study demonstrates that clinicians recommended breast cancer screening aligned with guidelines for those with 20% lifetime risk, regardless of whether risk was based on RiskScore or on Tyrer-Cuzick alone.

Poster: Germline Genetic Profiles of Women with Ovarian Malignancies: A Myriad Collaborative Research Registry Study (Abstract #: 5585) Date: Monday, June 3, 2024 Time: 9:00 am 12:00pm CT Description: This data shows that over 15% of patients with ovarian cancer have BRCA1/2 (12.5%) or Lynch syndrome (2.6%) pathogenetic variants varying by race, age, and tumor site. Noted disparities indicate the importance of universal testing in patients with ovarian cancer.

Poster: Germline Genetic Profiles of Women with Uterine Cancer: A Myriad Collaborative Research Registry Study(Abstract #: 5617) Date: Monday, June 3, 2024 Time: 9:00 am 12:00pm CT Description: There are significant differences in germline testing results for women with uterine cancer by race, ethnicity, and age, especially in genes associated with Lynch syndrome. This has implications for immunotherapy eligibility in the advanced and recurrent setting. More work needs to be done to identify targetable mutations in minority populations.

Poster: Neoadjuvant combination treatment of olaparib and pembrolizumab for patients with HRD-positive advanced ovarian cancer (Abstract #: 5545) Date: Monday, June 3, 2024 Time: 9:00 am 12:00pm CT Description: This study shows that neoadjuvant combination therapy of olaparib and pembrolizumab is effective and tolerable in patients with HRD-positive advanced ovarian cancer. BRCA1/2 mutations are associated with the efficacy of combination therapy.

Myriad Oncology Innovations Myriad continues to expand its oncology portfolio and expertise through product innovations and the addition of new team members, including the appointment of George Daneker Jr., MD, who is the president and chief clinical officer of oncology. Myriads Precise Oncology Solutions portfolio features comprehensive germline and somatic testing options, including the MyRisk Hereditary Cancer Test with RiskScore, Precise Tumor Test, Prolaris Prostate Cancer Prognostic Test, EndoPredict Breast Cancer Prognostic Test, Folate Receptor Alpha (Fr) Test, and Myriads two FDA-approved companion diagnostic tests: MyChoice CDx HRD Companion Diagnostic Test and BRACAnalysis CDx Germline Companion Diagnostic Test.

Ongoing oncology developments include:

MRD research collaborations. In the past year, Myriad has announced several important research collaborations: a retrospective study of MRD efficacy in metastatic breast cancer with researchers at Memorial Sloan Kettering Cancer Center (MSK), a retrospective analysis of MRD utility in metastatic renal cell carcinoma with clinicians at The University of Texas MD Anderson Cancer Center, and a prospective pan-cancer study with MRD researchers at the National Cancer Center Hospital East in Japan. Early results from the research collaboration with MD Anderson will be shared at ASCO as a poster.

As we continue to innovate and grow our oncology business, our vision remains centered around advancing oncology care for all patients, said Dr. Daneker. Our new research and product innovations underscore our commitment to partnering with oncologists, academic institutions and other healthcare partners to expand access to genetic and genomic testing, create equitable testing solutions for all, and provide data-driven insights that can better inform clinical care and improve outcomes for patients.

About Myriad Genetics Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit http://www.myriad.com.

Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the data and information that the company plans to present at the 2024 ASCO Annual Meeting and updates on upcoming product innovations including MRD and liquid biopsy testing. These forward-looking statements are managements expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the companys filings with the U.S. Securities and Exchange Commission, including the companys Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the companys Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Investor Contact Matt Scalo (801) 584-3532 IR@myriad.com

Media Contact Glenn Farrell (385) 318-3718 PR@myriad.com

Continued here:
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO Annual ... - GlobeNewswire

Ambry Genetics and PacBio Announce Collaboration To Sequence up to 7000 Human Genomes – Technology Networks

Register for free to listen to this article

Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Ambry Genetics, along with PacBio (NASDAQ: PACB), announced their companies selection by the University of California, Irvine (UCI) and the GREGoR Consortium (Genomics Research to Elucidate the Genetics of Rare diseases) to support the Pediatric Mendelian Genomics Research Center (MGRC) program to better understand the underlying biology of rare diseases.

The GREGoR Consortium is a National Institutes of Health-funded collaborative effort which aims to transform the landscape of Mendelian disease research by identifying the underlying genetic cause of rare disease in samples from individuals for whom prior genomic analysis did not yield answers. This ambitious research, among the largest programs of its kind, will use long-read sequencing technology to sequence and analyze up to 7,000 human whole genomes over three years, with a focus on developing new insights into rare disease etiology.

Subscribe to Technology Networks daily newsletter, delivering breaking science news straight to your inbox every day.

This pioneering initiative unites leading genomics researchers who will work collaboratively to incorporate innovative methods for understanding the biology of rare disease including phenotyping, variant identification, and functional analysis of both coding and non-coding sequence alterations. By using highly accurate 5-base, long-read sequencing technology, the researchers hope to discover new rare variants and to understand the role of epigenomics on disease manifestation. By building new analysis pipelines for these genomic and epigenomic data, the researchers hope to discover new Mendelian gene variations and to better categorize previously identified variants of unknown significance.

Over the past few years, weve collaborated with leading genomics researchers around the world to advance the scientific communitys understanding of the genomic basis of rare disease, said Christian Henry, President and Chief Executive Officer of PacBio. This project with the GREGoR team represents a significant step forward for us. We hope that by partnering with scientists at U.C. Irvine and geneticists from Ambry Genetics, we will not only be able to help families better understand the underlying causes of rare disease, but also to identify new analysis pipelines that can speed this process for other labs.

Through this collaboration, we will continue to advance the scientific communitys understanding of rare disease and to support both patients enrolled in this study and others whose exomes were sequenced previously through our Patient for Life program, said Tom Schoenherr, CEO of Ambry Genetics. This collaboration is an example of our steadfast commitment to excellence in genomics and relentless pursuit of innovation, which has been a driving force behind our work since we launched our first clinical offering for rare disease diagnosis more than 20 years ago.

Read the original post:
Ambry Genetics and PacBio Announce Collaboration To Sequence up to 7000 Human Genomes - Technology Networks

Study: Good Sleep Habits Linked to Lower Heart Disease Risk – Health.com

Having a consistent sleep schedule and regularly getting enough shuteye may lower your risk of cardiovascular disease, coronary heart disease, and stroke, according to new research.

Its well-established that sleep is a fundamental part of health, and not getting enough sleep can be harmful to your health. Disrupted sleep due to shift work has been linked to a higher risk of developing diabetes or having a heart attack. And getting too much or too little sleep has been linked to a higher risk of infection.

This latest study, published in JAMA Network Open in April, similarly came to the conclusion that good sleep is linked to better health. But interestingly, they found that the association between consistently good sleep and lowered risk of cardiovascular disease was true regardless of a persons genetic risk for developing the disease.

Our results further suggested that individuals with a higher genetic predisposition may benefit from persistent favorable sleep patterns, Xiaomin Zhang, MD, PhD, MPH, study author and professor of occupational and environmental health at the Huazhong University of Science and Technology Tongji Medical College, told Health.

Heres what experts had to say about the new research, the connection between healthy sleep patterns and heart health, and tips for consistently sleeping well.

Toa55 / Getty Images

This new study builds upon research published last year in the European Heart Journal, which found that people who maintained healthy sleep patterns over a two to five year period reduced their risk of cardiovascular disease.

Further investigating this finding, Zhang and her colleagues collected data on the sleep habits of more than 15,300 people in China who were retired. The average age in the cohort was about 66 years old, and about 58% were women. None of the participants had cancer or cardiovascular disease when the study began.

Participants filled out questionnaires and had a medical exam at the beginning of the study, and then again five years later.

The questionnaire asked people to report their sleeping habits, including their bedtime, sleep duration, sleep quality, and any midday napping. From there, the research team used data to determine if a persons sleep habits were persistently favorable or unfavorable.

Favorable sleep meant people were following four habits: getting 7 to 8 hours of sleep every night, going to bed between 10:00 p.m. and midnight, reporting good or fair sleep quality, and taking a midday nap for no more than an hour.

In addition to these sleep questionnaires, researchers used genotyping to assess participants genetic risk for developing stroke and coronary heart disease.

In the end, Zhang and her colleagues found that people who reported consistently favorable sleep habits had a lower risk of developing coronary heart disease, cardiovascular disease, and stroke. This was true regardless of a persons genetic risk for these diseases.

People who reported favorable sleeping habits at both points in the study had a 16% lower risk of coronary heart disease and a 34% lower risk of stroke.

For participants who both slept well consistently and had a low genetic risk, they saw a 35% lower risk of coronary heart disease and a 52% lower risk of stroke as compared to people on the other end of the spectrum, who were at high risk for cardiovascular disease and had poor sleep habits.

It is not surprising, but it is good additional supportive data to indicate the link between sleep and cardiovascular disease, Ashish Sarraju, MD, a staff preventive cardiologist at Cleveland Clinic who was not involved with the research, told Health.

Importantly, the studys findings emphasize that even people with a high genetic risk for stroke and coronary heart disease risk can lower their risk for these conditions by maintaining good sleep habits.

Of course, those at genetic risk are likely to have an overall higher risk for cardiovascular disease, said Sarraju. But there is no reason to believe that sleep is less important in those patients.

The link between sleep health and heart health is a strong one. The American Heart Association lists sleep on its Lifes Essential 8 list, which includes the most significant lifestyle factors for preserving cardiovascular health.

According to Zhang, lack of sleep or inconsistent sleep habits may affect heart health by causing inflammation and metabolic imbalances, or disruptions in how the body metabolizes food and gets rid of waste.

Poor sleep hygiene also disrupts circadian rhythm, which has been linked to issues such as hypertension.

Sleep patterns can be linked to high blood pressure and stress, Sarraju added.

Beyond just unfavorable sleep, not getting enough shuteye due to sleep disorders can also impact heart health. Specifically, obstructive sleep apnea is linked to both poor sleep and increased risk for cardiovascular disease.

Because of these associations, doctors should ask about sleep quality and quantity as they assess a persons cardiovascular disease risk, Sarraju said, especially if the patient has high blood pressure. Addressing these poor sleep patterns or sleep disorders will likely, in turn, improve heart health.

Even if a person does have a higher risk of developing cardiovascular disease, this new study and others show that patients are not 100% chained to genetics, Sarraju explained. Modifying risk factors still has an effect in decreasing cardiovascular disease in those patients.

Getting good sleep regularly is often easier said than done. Adults should get between seven and nine hours of sleep each night, and its recommended that people go to bed and wake up at the same time every day. But this consistency may not be as easy for people who work, people who are raising children, or others with busy, changing schedules.

But whenever possible, people should follow recommendations for good quality sleep from the Centers for Disease Control and Prevention (CDC). These guidelines include exercising during the day, avoiding large meals, caffeine, and alcohol before bed, sleeping in a quiet, dark, and cool room, and avoiding screens 30 minutes before bedtime.

In general, these are actionable steps that people can incorporate into their nighttime routinesthis might be especially good news for people who are genetically predisposed to heart disease.

Genetic factors are inherent, Zhang said. Sleep patterns can be actively managed and adjusted.

Read this article:
Study: Good Sleep Habits Linked to Lower Heart Disease Risk - Health.com

Study finds gene variants tied to breast cancer risk in Black women – STAT

Hundreds of genetic variants can nudge someones risk of breast cancer up or down or towards a particular subtype. The studies identifying those gene variants, though, have largely involved people with European ancestry and thus give a less accurate picture of breast cancer risk for people who are not white.

Thats beginning to change. Last week, researchers published a genome-wide association study on breast cancer in roughly 40,000 people of African descent in Nature Genetics, marking a leap forward in scientists knowledge of breast cancer genetics in people of African ancestry.

Before we started this study in 2016, there were just several thousand cases for Black Americans. It was a very small number, said Wei Zheng, the studys senior investigator and a cancer epidemiologist at Vanderbilt University. This study combined data from dozens of other studies and included genetic data for thousands of new participants, making it the largest combined breast cancer genetics study done with people with African ancestry.

Specifically, the study compiled data from about 30 different studies investigating breast cancer in African or African American people. About 18,000 of them had breast cancer, while the other 22,000 were healthy controls, and investigators were able to scour their genetic data for specific variations that seemed closely related to breast cancer. The statistical power that comes with such numbers enabled the team to make two key advances.

First, the team found 12 loci, or locations in the genome, that showed a significant association with breast cancer. Of those, the team identified variants of three genes that appear to increase the risk of triple negative breast cancer, one of the most aggressive subtypes. Since everyone has two copies or alleles of each gene, that means someone could have anywhere between one and six risk-related alleles of these three genes. Those who had all six risk-related alleles had roughly double the chance of getting triple negative breast cancer than those who only had three.

That could provide a foothold for scientists to begin predicting who might get this aggressive form of breast cancer, and it might offer an opportunity to better understand the biology of triple negative breast cancer by highlighting genes that seem to be important. Finally, we have enough data to drill down to estrogen negative and triple negative breast cancer, which are twice as common in the African American population as any other population, said Julie Palmer, an author of the study and a cancer researcher at Boston University.

The other advance came when the researchers used the data to build a breast cancer risk prediction model for people with African ancestry. Such models take into account hundreds of different genetic variants that can slightly push breast cancer risk up, adding them all up into a polygenic risk score.

In the past, these scores always performed better for white people than Black people, mainly because theres so much more research done in people with European ancestry a combined total of more than 100,000 participants for breast cancer. Polygenic risk scores have had an AUC, a measure of the models performance, of about 0.63 for people with European ancestry compared to 0.58 for the African ancestry population. When researchers combined the data from this study into their new model, however, that figure rose to 0.60. That equates to the model being able to correctly distinguish between someone whos likely to get breast cancer and someone who isnt about 60% of the time.

Even if this work is validated in other studies, as it still needs to be, that figure is not too useful for most individuals. An astute observer might note an AUC of 0.63 is only passably better than a coin toss. Thats an indication polygenic risk scores dont perform as well overall as scientists would like even at their best. When polygenic risk scores are combined with other breast cancer risk factors, like age of first childbirth or breast density, were still not very good at predicting breast cancer, Palmer said.

But research is continually improving on that. The hope is, one day, these scores will help scientists build tools that can reliably distinguish people who are more likely to get breast cancer and thus might have more to gain by beginning screening earlier or more frequently. Or, conversely, they could help weed out people who arent likely to get breast cancer and could thus screen less. If you dont need it, then why do it? said Laura Fejerman, a cancer researcher and epidemiologist at the University of California, Davis.

Polygenic risk scores might already be able to provide some of that context for a small minority of people, Fejerman added. For the 1% of people with the highest polygenic risk, their lifetime risk was a little bit above 30%, Fejerman said. That could be an argument for them to screen more often, even if they had no other risk factors. If you learn that, you might be more on top of your screening than most people who maybe let three years pass. So, if you could get the highest-risk women to screen every year, that would be a big benefit.

Without datasets in non-European ancestry populations, other racial demographic groups could be left out of that progress. In that sense, this new paper is definitely a big step forward for achieving racial equity, said Swati Biswas, a statistician and cancer researcher at the University of Texas at Dallas who did not work on the study.

In particular, the data are needed if scientists ever hope to create a unified polygenic risk score that works for everyone. At the moment, many models rely on racial categorization Black people use an African ancestry model; white people use a European model. But using such models in clinical practice isnt optimal, pointed out Jennifer James, a sociologist who studies breast cancer and bioethics at the University of California, San Francisco.

Imagine someone whose ancestry is 5% African and 95% European, but who also happened to inherit breast cancer risk alleles that were only found in the African ancestry population. That would mean the African ancestry polygenic risk model might work better for them, even if they didnt identify as Black themselves. You could be 1% Black, but the one thing you got was that allele, James said. We need to move towards a unified polygenic risk score.

That still wont be enough to end the breast cancer mortality gap between Black and white people, even if scientists created a perfectly accurate polygenic risk model, James added. Thats because part of the reason for the disparity has to do with the health care system writ large, not subtle biological differences across populations.

We know Black women have a longer time to diagnosis, longer time from diagnosis to treatment, James said. If everyone had equal access to healthcare, that would do more to close gaps in mortality than tweaking prediction models. I want when someone finds a lump in their breast or needs a mammogram, they have equal access to care.

Read the original here:
Study finds gene variants tied to breast cancer risk in Black women - STAT

Asking the Right Questions about Genetic Engineering – The University of Chicago Divinity School

Reservations about human genetic engineering generally fall into two camps: those who worry it is unnatural and those who worry it will be unfair. The ways these concerns are deployed are often unhelpful, but they point us toward real areas of concern where religious voices are valuable.

We can wave aside the superficial versions of these worries easily. The first is far too general in its condemnation. Genetic engineering is unnatural, but so is nasal spray. The whole project of medicine is an effort to make us healthier than we find ourselves naturally. If we are going to condemn human bioengineering because it is unnatural, wed have to find an argument that would not condemn all medical technology.

The second concern, rather than condemning too much technology, is often not about technology at all. Walter Isaacson, in an interview after writing a book on the subject, commented that, One of the problems when people discuss technology is that they often speak as if theyre afraid of technology when what theyre afraid of is capitalism. When my students share worries about an engineered human future, they are not usually afraid of genetics as some scary frontier they dont remember a time when we couldnt program DNA like computer code. What older generations may assume is still science fiction using an engineered virus to alter genes and cure a disease! my students simply take for granted (these techniques have already received FDA approval). No, my students tend to be afraid that new technologies will reinforce existing inequalities and systems of oppression. They arent worried about genetic technology; they are worried about genetic capitalism.

Worries about capitalism dominate dystopian depictions of our bioengineered future. My students regularly reference Gattaca, a movie which depicts a future with a strict class division between those who have been genetically engineered and those made the old-fashioned way, with only the former given access to professional opportunities. (Students bring up Gattaca often enough that I suspect high school biology teachers must all show the film in class).

In stories like Gattaca, nothing goes wrong with the bioengineering itself (stories of experimental medicine going wrong and producing zombies is a whole other genre). The problem in these movies is that successful bioengineering literally incarnates social inequality. These movies make visible the present reality that inheritance restricts our destinies. They are myths about capitalism as much or more than technology.

So, the objection that genetic technology is unnatural can fail because it criticizes too much technology, and the objection that it is unfair is inadequate because it may not criticize technology at all. But each of these concerns can point in a helpful direction, and more sophisticated versions of these arguments deserve consideration.

First, it is a thin definition of nature that calls all uses of technology unnatural. But there are different ways in which a technology can alter nature. Some technologies facilitate and reinforce existing relationships of care; others warp such relationships. To treat a childs cancer with chemotherapy isnt natural, but caring for a sick child certainly is. To select your future childs traits from a menu seems unnatural in a fundamentally different way. The former uses new technology to aid an ancient vocation of care. The latter introduces a novel power dynamic into intimate relationships, changing parents into consumers and children into products. Calling such engineering unnatural may be a shorthand for legitimate concerns about how these practices could distort relationships at the heart of human life.

Second, there are concerns about capitalism and genetic engineering that pertain directly to these technologies. Unfortunately, our ideas about justice have become so dominated by concerns about social oppression that we struggle to see anything underneath relations of power. We can forget the biology beneath sociality. If our moral aspirations are limited to achieving equity, we may not anticipate that a human population which radically alters its biology might be equally and freely victim to its own lack of foresight. We have an array of needs food, water, shelter as a result of having bodies, needs that we should strive to meet equitably. But bodies are more than things with needs; the fact that we are genetically diverse, ecological bodies shapes our goods and our experience of them. Genetic variation undergirds our social life in ways we may not recognize until they are removed by the flattening effects of biotechnology. I worry that, if we miss that fact, we may welcome Huxleys brave new world, as long as it comes with universal engineering and single-payer soma distribution.

We might imagine a just biotechnological future in which all races and classes have access to opportunities to engineer their children. But such a society, despite its social justice, may be worse off than one without genetic engineering, even if it is healthier, taller, and more athletic. We shouldnt just worry about capitalism making the future unfair. We should also worry about consumerism bioengineering a banal human monoculture (a concern that is intrinsic to the potential homogenizing effects of the technology). Yes, we should worry about a future where some people are born into a genetic ghetto, but we should probably also worry about a future where all people are born into a genetic suburb. Seeing that danger requires that we think about more than social justice when we think about genes and capitalism.

Refocusing moral concern on what is natural and bodily is a task for which religions may be critical. One reason why I value the work of religious ethicists in addition to philosophers is that religions often maintain closer contact with the messiness of bodily life. Religious communities tend to remain in touch, through spiritual disciplines, ritual, and confession, with the biological basis of human flourishing. They should be less prone to forget the limits that bodies put on agency. Religions can help us articulate visions of the human good that have positive content, rather than just negative condemnations of injustice. They can help us learn the lesson that there are realities sacred, natural, or both before which we ought to hold back, that there are mysteries to be respected, not removed.

Featured image by National Cancer Institute/Unsplash

Original post:
Asking the Right Questions about Genetic Engineering - The University of Chicago Divinity School

AI-enhanced integration of genetic and medical imaging data for risk assessment of Type 2 diabetes – Nature.com

This study comprised two primary analyses: a genetic-centric analysis (Analysis 1; detailed in Fig.1 and the Methods section) and a genetic-imaging integrative analysis (Analysis 2; detailed in Fig.2 and the Methods section). Data used in the two analyses are summarized (Supplementary TableS1). A total of 68,911 participants from the TWB were included in the analysis (Fig. S1).

The dataset containing information from 60,747 individuals after data quality control (QC) was divided into several subsets: (i) The genome-wide association study (GWAS) samples (Dataset 1, N=35,688), training samples (Dataset 2, N=12,236; Dataset 4, N=40,787), and validation samples (Dataset 3, N=3060; Dataset 5, N=10,197). For classification analysis, testing samples comprised Dataset 6 (N=8827) and Dataset 7 (N=936), while for prediction analysis, they were represented as Datasets 6 (N=8827) and Dataset 7 (N=936); B Sample size. Total sample size, along with the number of cases and the number of controls, are shown for each of the four phenotype definitions in Datasets 1 7; C Phenotype definition criteria. The definition and sample size for the four Type 2 Diabetes (T2D) phenotype definitions is shown. D Analysis flowchart. The analysis flow comprises three steps, starting with selecting T2D-associated single nucleotide polymorphisms (SNPs) and polygenic risk score (PRS), then selecting demographic and environmental covariates, and the best XGBoost model was established using the selected features. As to the first step, SNPs can be chosen from A our own GWAS with an adjustment for age, sex, and top ten principal components (PCs), B published studies based on single ethnic populations, and C published studies based on multiple ethnic populations. Source data are provided as a Source Data file.

Phenotype Definition IV was used as an example to illustrate the process. The data containing information from 7,786 individuals were divided into four subsets: a training dataset (N=4689), a validation dataset (N=1175), and two independent testing datasets (N=1469 for the first dataset and N=444 for the second independent dataset). Subsequently, the best XGBoost model was established. B Flowchart of PRS construction. The Polygenic Risk Score (PRS) was constructed using PRS-CSx, utilizing genome-wide association study (GWAS) summary statistics from the European (EUR), East Asian (EAS), and South Asian (SAS) populations obtained from the analysis of the DIAGRAM Project. Source data are provided as a Source Data file.

We evaluated the prediction performance under different scenarios hierarchically (the best scenario at a previous variable was given for a discussion of the next variable) in the following order: the sources and significance levels of T2D-associated SNPs (Fig.3A and Fig. S2), T2D phenotype definitions (Fig.3B), family history variable combinations (Fig.3C and Fig. S3), demographic variable combinations (Fig.3D), demographic and genetic variable combinations (Fig.3E), and SNP and PRS combinations (Figs.3F and 3G). The findings are summarized as follows: First, using T2D-associated SNPs from the previous large-sample-size GWAS11 as predictors had the highest AUC of 0.557, but its AUC was not significantly higher than that used the SNPs identified by our smaller-sample-size GWAS under different thresholds of statistical significance (Fig.3A), although our GWASs did identify some T2D-associated SNPs (Fig. S4). Second, the phenotype defined by self-reported T2D with HbA1C6.5% or fasting glucose 126mg/dL (i.e., T2D Definition IV) had the highest AUC of 0.640. Its AUC was significantly higher than the AUCs of the other three T2D definitions (Fig.3B). Third, sibs disease history had a significantly higher AUC of 0.732 than parents disease history with an AUC of 0.670 (p=0.009). Moreover, additive parent-and-sib disease history had the highest AUC of 0.758. Its AUC was significantly higher than parent-only (p<0.001) (Fig.3C). Fourth, a joint effect of age, sex, and additive parent-sib disease history had the highest AUC of 0.884. Its AUC was significantly higher than other demographic variable combinations, except for the combination of age and additive parent-sib disease history (Fig.3D). Fifth, whatever SNPs were included or not, demographic and PRS combinations outperformed the models without incorporation of PRS (Fig.3E), although genetic factors only improved up to 3% of AUC conditional on demographic characteristics (age, sex, and family history of T2D). Finally, given T2D-associated SNPs, AUC significantly increased if PRS was included (Fig.3F); T2D-associated SNPs provided a limited additional effect if PRS was already included (Fig.3G).

A bar chart displays AUC. The two-sided DeLong test examined the difference between AUCs. Bonferronis correction was applied to control for a family-wise error rate in multiple comparisons. Symbols *, **, and *** indicate p-values<0.05, 0.01, and 0.001, respectively. A SNP selection. Model predictors were SNPs selected from published studies or our GWAS under different p-value thresholds, where our GWAS association test is a two-sided Wald test for the slope coefficient in a logistic regression. The average AUCs of prediction models for four phenotype definitions were compared. B T2D Phenotype Definition. In addition to including the selected variables in Fig.3A, the AUCs of four phenotype definitions were compared. C Family history of T2D. In addition to including the selected variables in Fig.3A, B, the AUCs of the four types of T2D family history (i.e., (i): parents (binary factor), (ii) sibs (binary factor), (iii) either parents or sibs (binary factors), and (iv) both parents and sibs (ordinal factor)) were compared. D Demographic variables. In addition to including the selected variables in Fig.3AC, the AUCs of different combinations of demographic factors, including age, sex, and family history of T2D, are compared. E PRS and demographic variables. In addition to including the selected variables in Fig.3AD, the AUCs of different combinations of genetic variables, including SNPs, PRS-CS, and PRS-CSx, and demographic variables, including age, sex, and family history of T2D, are compared. F Impact of including PRS after SNPs. The AUCs of the models that consider SNPs, SNPs+PRS-CS, and SNPs+PRS-CSx as predictors are compared. G Impact of including additional SNPs after PRS. The additional 137 SNPs were collected from published studies (Supplemental Text2). The AUCs of the models that consider additional SNPs given PRS in the model are compared. Source data are provided as a Source Data file.

Among different prediction models, the model with predictors PRS-CSx, age, sex, and family history of T2D had the highest AUC 0.915 (Fig.4A) for Type VI definition of T2D based on the first testing dataset (i.e., Dataset 6 in Fig.1). The optimal threshold, determined by the Youden index, for the fitted value that used to predict T2D or non-T2D in the XGboost model was 0.16. The Accuracy, Sensitivity, Specificity, and F1 indices were 0.843, 0.844, 0.843, and 0.672, respectively. Furthermore, the model was tested in the second independent testing dataset (i.e., Dataset 7 in Fig.1), and a promising result similar to the first testing dataset was found: AUC=0.905, Accuracy = 0.843, Sensitivity = 0.846, Specificity = 0.842, and F1=0.644. AUCs are also provided for the other three T2D definitions (Fig. S5).

A AUCs of all models based on Phenotype Definition IV. A heatmap summarizes the AUCs of all models based on Phenotype Definition IV (i.e., T2D was defined by self-reported T2D, HbA1c, and fasting glucose). The genetic variables are shown on the X-axis, and the demographic variables are shown on the Y-axis. B Positive correlation between PRS and T2D odds ratio. In each decile of PRS based on PRS-CSx, the odds ratio of T2D risk and its 95% confidence interval were calculated based on an unadjusted model (blue line) and an adjusted model considering age, sex, and T2D family history (red line). The reference group was the PRS group in the 4060% decile. The horizontal bars are presented as the odds ratio estimates (square symbol) +/ its 95% confidence intervals (left and right ends) at a PRS decile. C High-risk group. In the chart, the figures from the inner to the outer represent (i) the case-to-control ratio, (ii) the number of cases, and (iii) the number of controls in the PRS decile subgroups. D Association of age, sex, T2D family history, and PRS with T2D. In the univariate analysis, the p-values for age, sex, family history, and PRS were 4.17 1020, 7.08 107, 9.41 1013, and 2.06 1013, respectively. In the multivariate analysis, the p-values for age, sex, family history, and PRS were 2.00 1016, 5.56 105, 1.43 1010, and 5.49 1013, respectively. E Risk factors for T2D. Kaplan-Meier curves reveal that Age (older individuals), sex (males), T2D family history (the larger number of parents and siblings who had T2D), and PRS (high decile PRS group) are risk factors (high-risk level) for T2D risk. F Median event time of T2D. Examples of the median event time for developing T2D are provided based on a multivariate Cox regression model, both without and with incorporating PRS. NA indicates not assessable. Source data are provided as a Source Data file.

The importance of each predictor was evaluated through a backward elimination procedure of variables. The optimal model incorporating age, sex, family history of T2D, and PRS achieved an AUC of 0.915. The AUC reductions upon removing individual variables are as follows: (a) Omitting the age variable resulted in an AUC of 0.839, representing a reduction of 0.076. (b) Excluding the sex variable resulted in an AUC of 0.905, with a decrease of 0.01. (c) Removing the family history of the T2D variable yielded an AUC of 0.881, with a reduction of 0.034. (d) Eliminating the PRS variable resulted in an AUC of 0.884, decreasing to 0.031. Based on the decrease in AUC, the impact size appears to be in the order of age > family history > PRS > sex. Additionally, we evaluated feature importance (see the Methods section), and the order of feature importance is family history > age > PRS > sex. Our findings consistently highlight age and family history as the most crucial risk factors for T2D.

Family history encompasses genetics and environment. We delved into the connection between the family history of T2D treated as a graded scale (0, 1, 2, 3, and 4) and the genetic component represented by the PRS. Through ordinal logistic regression, we observed a beta coefficient of 0.808 and an associated odds ratio (OR) of 2.24 (p=1.65 10296). The remarkably small p-value emphasizes the robust statistical significance, signaling a substantial association between the PRS and familial T2D status. For each incremental unit rise in an individuals PRS, their odds of belonging to a higher family history category for T2D increase by 2.24 times. This implies a tangible shift in the likelihood of different family history classifications as the PRS changes. The findings underscore a strong statistical link between genetic predisposition, as captured by the PRS, and the gradation of family history of T2D.

Furthermore, we calculated the Population Attributable Risk (PAR) by dichotomizing PRS into a high-risk group (PRS tercile >80%) and a non-high-risk group (PRS tercile <80%). Among the 59,811 participants, the breakdown was as follows: high PRS with family history (N=5473), high PRS without family history (N=6489), non-high PRS with family history (N=16,054), and non-high PRS without family history (N=31,795). The PAR estimate was 10.17%, indicating that 10.17% of the family history of T2D is attributed to genetic heritability. If considering a broader definition of the high-risk group (PRS tercile >60%) and non-high-risk group (PRS tercile <60%), the PAR estimate increased to 18.41%.

Further consideration of environmental factors, including education level, drinking experience, exercise habits, the number of exercise types, and SNP-SNP interactions with and without SNPs main effect, did not improve T2D prediction (Supplementary TableS2). Considering model parsimony, the final model did not include these environmental factors and SNP-SNP interactions. In addition to prediction models, classification models were also established. The AUCs in classification models (Fig. S6) were generally slightly higher than those in prediction models (Fig. S5).

The positive association between PRS and T2D risk is shown (Fig.4B). Compared to the participants in the 4060% PRS decile group, those in the top 10% decile group had a 4.738-fold risk of developing T2D (95% confidence interval: 3.1477.132, p<0.001) and a 4.660-fold risk (95% confidence interval: 2.6828.097, p<0.001) after adjusting for age, sex, and family history. In addition, we performed a stratified analysis across various combinations of age subgroups, sex subgroups, and family history subgroups to identify high-risk subgroups, where age was stratified into four subgroups based on quartiles: 025%, 2550%, 5075%, and 75100%, corresponding to age subgroups of 43, 4352, 5259, and >59 years of age, respectively (Fig. S7). We identified a high-risk subgroup of women who were older than 59 and had a family history of T2D. The ratio of case vs. control sample size was as high as 7.313.0-fold in the 80100% decile groups (Fig.4C). The ratio was much higher than a 1.6-fold that did not consider PRS (i.e., PRS at 0100%) (Fig.4C). Due to ambiguity or instability in the evidence for other combinations, we chose not to report them.

Among 8347 non-T2D participants at baseline in the first testing dataset of 8827 participants, 220 reported T2D in the follow-up. The Cox regression analyses considered two types of time scales and three types of sex variable treatment and obtained a consistent result (Supplementary TableS3). Using the analysis in which we considered time-on-study as the time-scale with age at baseline, sex, family history of T2D, and PRS as covariates for illustration, age, sex, family history of T2D, and PRS were all significantly associated with T2D (p<0.001) (Fig.4D). Increased age, higher PRS, and stronger T2D family history had a higher T2D risk. The elderly male, with a strong family history and high PRS, had a severe T2D risk (Fig.4E for multivariate Cox regression and Fig. S8 for univariate Cox regression). We also provided the predicted time-to-event (week) (Fig.4F). For example, a 50-year-old man with one of his family members had T2D will achieve median T2D-free time after 460 weeks (95% CI, 384NA). The median time to develop T2D was shortened to 419 weeks (95% CI, 384NA) after considering a standardized PRS of 0.66 (equivalent to a PRS risk subgroup in the top 25% of the population).

A linear regression analysis was performed to assess the impact of exercise on HbA1c. Multiple testing for 110 analyses was corrected using Bonferroni correction, and the significance level was set as 4.5 10-4. It was observed that individuals engaging in regular exercise experienced a significant reduction in HbA1c by an average of 0.09% mg/dL (p<0.001) compared to those who did not engage in regular exercise. Moreover, individuals with a high PRS who engaged in exercise demonstrated a greater reduction in HbA1c (0.13% mg/dL) than those with a low PRS (0.08% mg/dL). The results also suggested that the T2D patients who regularly engaged in exercise can have a noteworthy improvement of 0.32% mg/dL in HbA1c than those T2D patients who did not exercise regularly. In addition, among the various types of exercise, walking for fitness exhibited the most robust reduction in HbA1c for all samples, including high and low-risk subgroups and both T2D and non-T2D groups (Fig. S9). On average, participants engaged in walking for fitness 18.30 times a month (standard deviation = 8.64) for approximately 48.13minutes per session (standard deviation = 22.92).

To investigate the early detection capability of our model for T2D, we performed an analysis focusing on 550 women participants older than 59 years, all of whom had a family history of T2D. We identified them as at high risk if they possessed a high PRS, even though they were initially reported as non-T2D at baseline. Thirty-six were changed to T2D, and 514 were still non-T2D at follow-up. We predicted their T2D status. G1 G4 are the groups of participants in true positive, false negative, false positive, and true negative, respectively (Fig.5A). We evaluated that G3 was indeed misclassified by our prediction model or our prediction had corrected the problem in the self-reported T2D by further investigating: (1) their follow-up time and current risk in the Cox regression model; (2) HbA1c and fasting glucose; (3) the accuracy of self-reported disease status.

A Four subgroups (N=550). B Survival rate (N=550). C Median survival time (N=550). P-values of G1 vs. G3, G2 vs. G3, and G4 vs. G3 were 0.092, 0.0014 (**), and 2.22 1016 (***), respectively. D Follow-up time (N=550). P-values of G1 vs. G3, G2 vs. G3, and G4 vs. G3 were 0.056, 0.32, and 0.14, respectively. E T2D risk (N=550). P-values of G1 vs. G3, G2 vs. G3, and G4 vs. G3 were 0.018 (*), 0.073, and 0.0039 (**), respectively. F HbA1c (N=550). P-values of G1 vs. G3, G2 vs. G3, and G4 vs. G3 were 2.21 1014, 0.0039, and 3.00 105; respectively; in the follow-up, p-values of G1 vs. G3, G2 vs. G3, and G4 vs. G3 were 1.50 10-13, 6.01 104, and 4.55 10-6, respectively. G Fasting glucose (N=550). In the baseline, p-values of G1 vs. G3, G2 vs. G3, and G4 vs. G3 were 2.06 10-12, 6.66 104, and 1.63 102; respectively; in the follow-up, p-values of G1 vs. G3, G2 vs. G3, and G4 vs. G3 were 8.30 108, 1.38 103, and 1.84 102, respectively. H Phenotype definition in G3 (N=395). Many individuals in G3 cannot satisfy the T2D Phenotype Definition IV. In Fig.5CG, two-sided Wilcoxon rank-sum tests were applied to compare group differences. The box plots center lines indicate the medians, the lower and upper boundaries of the boxes represent the first and third quartiles, and the whiskers extend to cover a range of 1.5 interquartile distances from the edges. The violin plots upper and lower bounds depict the minimum and maximum values. Source data are provided as a Source Data file.

The Kaplan-Meier curve for each subgroup is depicted (Fig.5B). The distributions of median survival time for each subgroup are illustrated (Fig.5C). The distributions of the time period from baseline to follow-up for each subgroup are presented (Fig.5D). The distributions of Type 2 diabetes (T2D) risk at follow-up for each subgroup are shown (Fig.5E). The distributions of HbA1c levels at baseline and follow-up for each subgroup are displayed (Fig.5F). The distributions of fasting glucose levels at baseline and follow-up are demonstrated (Fig.5G).

First, compared to G4 (true negative), G3 had a significantly lower T2D-free probability (Fig.5B), shorter median survival time (Fig.5C), higher T2D-risk under similar follow-up time (Fig.5D and 5E), higher HbA1c (Fig.5F), and higher fasting glucose (Fig.5G). Second, compared to G1 (true positive), G3 had a comparable survival rate (Fig.5B), median survival time (Fig.5C), and T2D-risk under similar follow-up time (Fig.5D and5E) but lower HbA1c (Fig.5F) and fasting glucose (Fig.5G). We didnt compare G2 and G3 because of the small sample size in G2. Finally, among the 395 participants in G3, 80.76% of them were removed from our previous analysis because their baseline HbA1c and fasting glucose violated the criteria for the phenotype definition (Fig.1C); 339 participants were removed because of their follow-up HbA1c and fasting glucose violated the formal T2D criteria; only 34 self-reported non-T2D were really non-T2D participants who had HbA1C<6.5% and fasting glucose <126mg/dL (Fig.5H). Overall, the results consistently indicate that G3 represents individuals in a pre-T2D stage, which our model can detect early.

The model that combined four types of image features performed best. Moreover, the model based on BMD image features exhibited a higher AUC, accuracy, specificity, and F1 than the models based on any other three types of images (Fig.6A). The models based on image features had an AUC of 0.898, higher than the ones of genetic information (AUC=0.677) and demographic factors (AUC=0.843). Integrating image features, genetic information, and demographic factors increased AUC to 0.949 in the first testing data (Fig.6B); the results for each of the four images are also provided (Fig. S10). The accuracy, sensitivity, specificity, and F1 of the model in the first testing data were 0.871, 0.878, 0.870, and 0.663, respectively, based on a classification threshold of 0.03. The model also performed reasonably well in the second testing dataset with AUC=0.929, Accuracy = 0.854, Sensitivity = 0.789, Specificity = 0.862, and F1=0.558. The results of a prediction model using tuned parameters are also provided (Supplementary TableS4). As no significant improvement was observed, this paper discusses the default model. According to the estimated feature importance in the best XGBoost model, all genetic factors (PRS), four types of medical images, and demographic variables provided informative features for risk assessment, such as PRS (genetics), family history and age (demographic factors), fatty liver (ABD images), end-diastolic velocity in the right common carotid artery (CAU images), RR interval (ECG images), and spine thickness (BMD images). Of the 152 medical imaging features, 125 were selected in the final model. (Fig.6C).

A Performance comparison of medical imaging data analysis. The area under the receiver operating characteristic (ROC) curve (AUC), accuracy (ACC), sensitivity (SEN), specificity (SPEC), and F1 score are compared for the integrative analysis of four types of medical images (All) and individual medical image analyses, including BMD, ECG, CAU, and ABD. B The model that combines four types of medical imaging, PRS, and demographic variables shows the highest AUC of 0.949. ROC plots and the corresponding AUC for the models considering medical image features (I), genetic PRS (G), and demographic variables, including age, sex, T2D family history (D), and their combinations. C An optimal model combining medical imaging, PRS, and demographic variables. The best models top 20 features with a high feature impact include the medical image, genetic, and demographic features. D Positive correlation between MRS and T2D odds ratio. In each decile of MRS based on four types of medical images, the odds ratio of T2D risk and its 95% confidence interval were calculated based on an unadjusted model (blue line) and an adjusted model considering age, sex, and T2D family history (red line), with the MRS group in the 4060% decile serving as the reference group. The horizontal bars are presented as the odds ratio estimates (square symbol) +/ its 95% confidence intervals (left and right ends). E High-risk group. The figures from the inner to the outer in the chart display (i) the case-to-control ratio, (ii) the number of cases, and (iii) the number of controls in the MRS decile subgroups. F Input page of the online T2D prediction website. Personal information, including age, sex, family history of T2D, PRS, and MRS, is input to calculate T2D risk. PRS and MRS are optional, and a reference distribution is provided. G Output page of the online T2D prediction website. Source data are provided as a Source Data file.

To address the challenges of practical clinical implementation in the best XGBoost model, we have proposed an alternative model that requires a limited number of features. We systematically calculated each features incremental area under the AUC by sequentially including those with the highest feature importance. We selected the top features showing a positive AUC increment. The analysis revealed that a sub-model incorporating only the following eight crucial variables: family history (from the questionnaire), age (from the questionnaire), fatty liver (from ABD images), spine thickness (from BMD images), PRS (from genetic data), end-diastolic velocity in the right common carotid artery (R_CCA_EDV) (from CAU images), RR interval (from ECG images), and end-diastolic velocity in the left common carotid artery (L_CCA_EDV) (from CAU images), maintains a commendable AUC of 0.939 (Fig. S11). This streamlined model significantly reduces the number of risk predictors while preserving high prediction accuracy, demonstrating promising potential for practical application in clinical settings. Moreover, the reduced number of risk predictors in the streamlined model alleviates concerns about model overfitting.

Each participants multi-image risk score (MRS) was calculated as the likelihood of being predicted as a T2D case using XGBoost, which analyzed the medical imaging features for T2D prediction. The odds ratio and its confidence interval for the association between MRS and T2D are shown by percentiles of MRS (Fig.6D). Compared to the participants in the 4060% MRS decile group, the risk of T2D increased with MRS. Of importance, we further identified that, for the men older than 54 years old with a family history of T2D, the case vs. control ratio of sample size was 9.3 in the 90100% MRS decile group, much higher than 1.3, which MRS was not considered (Fig.6E).

We have established a website where users can calculate their T2D risk online. To obtain the risk assessment, users are required to provide age, sex, and family history of T2D, and they can optionally provide PRS and MRS (Fig.6F). PRS and MRS can be entered manually or uploaded as a file (Supplemental Text1). Additionally, we have provided PRS and MRS risk percentages based on the study population as a reference. The online risk assessment offers information, including the risk of developing T2D over 3, 5, and 7 years, T2D-free probability, and T2D risk with and without considering PRS (Fig.6G). The assessment takes into account both PRS and MRS (Fig.6G). For example, consider a 50-year-old male with a family history of T2D and PRS 1.5 and MRS 1.5. Without considering PRS, the risk (probability) of developing T2D after a 7-year follow-up is 0.23. However, when PRS is considered, the risk increases to 0.37. Furthermore, considering MRS further increases the risk to 0.81. The online tool provides these valuable insights to users based on their input data.

Link:
AI-enhanced integration of genetic and medical imaging data for risk assessment of Type 2 diabetes - Nature.com

Enhancing Chickpea Crop Improvement With Wild Chickpea Genes – Technology Networks

Register for free to listen to this article

Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

The studyCicer super-pangenome provides insights into species evolution and agronomic trait loci for crop improvement in chickpea,published in Nature Genetics, provides insights into the evolutionary history and divergence time of the Cicer genus, sequencing the genomes of eight wild Cicer species and comparing them with two cultivated chickpea varieties.

The study also constructs a graph-based super-pangenome that can help identify and transfer valuable genes from wild species to cultivated ones.

Director of Murdoch UniversitysCentre for Crop and Food InnovationProfessor Rajeev Varshney, who coined the term super-pangenome in 2019 inTrends in Plant Science, said the findings in the new study could accelerate crop improvement globally.

Subscribe to Technology Networks daily newsletter, delivering breaking science news straight to your inbox every day.

The Cicer super-pangenome offers a powerful way to study chickpea genes to perform association analyses and determine the most important traits for our farming industry.

Our study found that the wild species have more genetic diversity and variations that could be useful for improving chickpea traits such as disease resistance, flowering time, and stress tolerance.

Traditional and modern breeding efforts have improved chickpea productivity, but more exhaustive steps have been needed to meet the growing worldwide demand.

Chickpeas are highly nutritious, economically significant and important contributors to soil fertility, fixing atmospheric nitrogen but chickpea production currently faces several biotic and abiotic constraints.

They are widely grown, with an annual global production exceeding 17 million tonnes.

In the context of Australia, chickpea production reached more than 2 million tonnes in 2017, but at present it is only 500,000 tonnes, so there is huge scope for enhancing local production to contribute to both environmental sustainability and growers profitability.

Reference:Khan AW, Garg V, Sun S, et al. Cicer super-pangenome provides insights into species evolution and agronomic trait loci for crop improvement in chickpea. Nature Genetics. 2024. doi:10.1038/s41588-024-01760-4

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.

Originally posted here:
Enhancing Chickpea Crop Improvement With Wild Chickpea Genes - Technology Networks

World-first AI algorithm developed at CHEO leads to rare disease diagnosis for families – CHEO

Harnessing the power of artificial intelligence (AI), CHEO researchers have developed a groundbreaking search algorithm that identifies children and youth who may have an undiagnosed rare genetic disease and refers them for genetic testing putting an end to their diagnostic odyssey.

The ThinkRare algorithm is incredibly exciting and promising because it means we can help families find answers and get the care and support they need sooner, said Dr. Kym Boycott, Senior Scientist at the CHEO Research Institute and Chief of Genetics at CHEO. This algorithm is a game changer. Using AI to scour CHEOs electronic health record based on set criteria, ThinkRare can accurately identify kids who may have an undiagnosed rare genetic disease and refer them to our clinic something that may have never happened without it.

Ten-year-old Antony Wistaff and hisfamily have spentcountlesshours at CHEO, callingit a second home. Antony wasbornprematurely in October 2013 and a few dayslaterunderwent emergency surgery at CHEO to place a shunt for hydrocephalus. But thatwasonly the beginning of whatwouldbecome a decade-long diagnostic journeyconsisting of more than 100 outpatientappointmentsacross six differentspecialtyclinics at CHEO, and 30 trips to the emergency department for variousreasons.

That was until recently, when the ThinkRare algorithm identified Antony as potentially having an undiagnosed rare genetic disease and flagged him for a referral to receive genome-wide sequencing testing a test that simultaneously analyzes the more than 5,000 genes that have been associated with rare disease and is now available clinically in Ontario.

The results of the genetictestingdiscoveredthat Antony has Chung-Jansen Syndrome a rare disorderresultingfrom a pathogenic variant in the PHIP gene. At present, the syndrome has been diagnosed in only about 400 people worldwide and itexplainedmany of Antonyshealth and behavioural challenges, includinghisdevelopmentaldelays, learningdifficulties, and large head size.

When we found out that Antony was diagnosed with Chung-Jansen Syndrome, it answered so many questions for our family, said Georges Wistaff, Antonys dad. This research brought a kind of peace to our house. Hadweknownthissooner, itwould have meantlessquestioning as parents, less stress, and more support becausewewould have had a cleardiagnosis for Antony. A little bit of blood and a simple test, answeredsomany questions.

To date, Think Rare, whichiscurrently operating as a researchprojectapproved by the CHEO ResearchEthicsBoard, isthree for three meaning the first three patients identified by ThinkRare and referred to genetics have received test results and been diagnosedwith a rare disease. Genetictestingisunderway for manyotherfamiliesidentified by ThinkRare.

Our goal is to flip the diagnostic care journey on itshead and start withgenetictestingearlier on the care pathway. By incorporating the ThinkRarealgorithmintoclinical care, wewillbe able to support CHEO clinicians and frontlineworkerswith the power of machine learning to find the needle in the haystack, added Dr. Boycott, whois a Tier 1 Canada Research Chair in Rare DiseasePrecisionHealth and Professor of Pediatrics at the University of Ottawa.

Work iscurrentlyunderway at CHEO to transition the ThinkRareprojectfrom researchintoclinical practice, with all the necessary patient privacymechanisms in place.

CHEO isuniquelypositioned to develop an impactfulalgorithmsuch as ThinkRarebecause of CHEOsinvestment in a robustelectronichealth record system, ourcommitment to innovation, our close collaboration betweenclinical and researchteams, and becausewe are the only pediatric healthcare centre in Eastern Ontario serving a widegeographic area. At CHEO, we have broughttogether all the necessaryelementswhenitcomes to making AI advancements in healthcare, said Dr. Jason Berman, CEO and Scientific Director, CHEO Research Institute, and Vice-PresidentResearch, CHEO.

The ThinkRareprojectwas made possible withfundingfrom the CHEO Foundation, the CHAMO Innovation Fund, and Ontario Genomics.

-30-

Media contact:

Jennifer Ruff Director of Communications CHEO Research Institute (613) 261-3979 jruff@cheo.on.ca

About the CHEO Research Institute

The CHEO Research Institute is a global centre of excellence in pediatric research that connects talent and technology in pursuit of life-changing research for every child, youth and family in the CHEO community and beyond. The CHEO Research Institute coordinates the researchactivities of CHEO and isaffiliatedwith the University of Ottawa. At the CHEO Research Institute, discoveries inspire the best life for everychild and youth. For more information, visitcheoresearch.ca.

More here:
World-first AI algorithm developed at CHEO leads to rare disease diagnosis for families - CHEO